Immunohistochemical double hit score enhances NCCN-IPI and is associated with detrimental outcomes in refractory or relapsing patients with diffuse large B cell lymphoma

Katharina T Prochazka; Florian Posch; Alexander Deutsch; Christine Beham-Schmid; Herbert Stöger; Leke Abdyli; Hildegard Greinix; Martin Pichler; Peter Neumeister

doi:10.1111/bjh.14912

Immunohistochemical double hit score enhances NCCN-IPI and is associated with detrimental outcomes in refractory or relapsing patients with diffuse large B cell lymphoma

Br J Haematol. 2018 Oct;183(1):142-146. doi: 10.1111/bjh.14912. Epub 2017 Sep 6.

Authors

Affiliations

¹ Division of Haematology, Department of Internal Medicine, Medical University of Graz (MUG), Graz, Austria.
² Division of Oncology, Department of Internal Medicine, Medical University of Graz (MUG), Graz, Austria.
³ Institute of Pathology, Medical University of Graz (MUG), Graz, Austria.
⁴ Research Unit for non-coding RNAs and genome editing in cancer, Medical University of Graz, Graz, Austria.
⁵ Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

PMID: 28875547
DOI: 10.1111/bjh.14912

No abstract available

Keywords: National Comprehensive Cancer Network-International Prognostic Index; diffuse large B cell lymphoma; double expressor lymphoma; outcome; prognosis.

Publication types

Letter

MeSH terms

Follow-Up Studies
Gene Rearrangement*
Humans
Immunohistochemistry / methods*
Lymphoma, Large B-Cell, Diffuse / diagnosis*
Lymphoma, Large B-Cell, Diffuse / genetics
Lymphoma, Large B-Cell, Diffuse / mortality
Prognosis
Proto-Oncogene Proteins c-bcl-2 / genetics
Proto-Oncogene Proteins c-bcl-6 / genetics
Salvage Therapy / methods
Survival Analysis
Treatment Outcome

Substances

BCL2 protein, human
BCL6 protein, human
Proto-Oncogene Proteins c-bcl-2
Proto-Oncogene Proteins c-bcl-6